Integra LifeSciences beats Q2 earnings and revenue forecasts, revising full-year revenue guidance upward to $1.654B-$1.695B.
Integra LifeSciences Holdings Corporation reported Q2 non-GAAP earnings per share of $0.56, exceeding estimates by $0.08. Revenue reached $418.7 million, a 0.7% year-over-year increase, beating forecasts by $1.16 million.
The company updated its full-year revenue guidance to a range of $1.654 billion to $1.695 billion, compared to the $1.68 billion consensus estimate. The prior guidance was not disclosed in the release.
The results reflect stronger-than-expected performance in the quarter, driven by demand in its medical technology segments.